{"id":"W2892185075","doi":"10.1200/jco.2017.35.15_suppl.tps3105","title":"A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Triple-negative breast cancer; Immunotherapy; Phases of clinical research; Antigen; Immune system; Neutropenia; Metastatic breast cancer; Cancer; Breast cancer; Clinical trial; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002518662,0.00175629,0.002217109,0.0003978435,0.0005624997,0.001079453,0.001015846,0.001439368,0.004879919],"category_scores_gemma":[0.001401071,0.0008897624,0.001399614,0.0004235638,0.001218991,0.001326574,0.0004416312,0.00314481,0.001166062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001002772,"about_ca_system_score_gemma":0.001876084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008966386,"about_ca_topic_score_gemma":0.002234625,"domain_scores_codex":[0.9992313,0.00041081,0.00003341169,0.000147494,0.00006427153,0.0001126991],"domain_scores_gemma":[0.9990246,0.0001367624,0.000201975,0.0001022768,0.00006857772,0.0004657436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8385581,0.1047894,0.004683968,0.0003475557,0.0008869189,0.0001128011,0.0002274037,0.001052468,0.01705647,0.0001441129,0.001602587,0.03053821],"study_design_scores_gemma":[0.5500445,0.4389632,0.007548268,0.0000173402,0.000267417,0.0001100376,0.00006558993,0.000596792,0.001028776,0.0001156707,0.001223846,0.00001858605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912281,0.0009717828,0.0006135934,0.0003674172,0.0001633535,0.004639009,0.0008269688,0.00006676059,0.001123006],"genre_scores_gemma":[0.9857848,0.001025822,0.00248475,0.0008618358,0.0002589707,0.005386299,0.001487528,0.00002547051,0.002684495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004879919,"threshold_uncertainty_score":0.01632494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09115560599467787,"score_gpt":0.4964976122619084,"score_spread":0.4053420062672305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}